IQVIA Holdings Inc
NYSE:IQV

Watchlist Manager
IQVIA Holdings Inc Logo
IQVIA Holdings Inc
NYSE:IQV
Watchlist
Price: 184.75 USD 1.83% Market Closed
Market Cap: 32.5B USD

IQVIA Holdings Inc
Cash Paid for Dividends

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

IQVIA Holdings Inc
Cash Paid for Dividends Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Paid for Dividends CAGR 3Y CAGR 5Y CAGR 10Y
IQVIA Holdings Inc
NYSE:IQV
Cash Paid for Dividends
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Cash Paid for Dividends
-$583m
CAGR 3-Years
-14%
CAGR 5-Years
-14%
CAGR 10-Years
-10%
Danaher Corp
NYSE:DHR
Cash Paid for Dividends
-$768m
CAGR 3-Years
-1%
CAGR 5-Years
-8%
CAGR 10-Years
-13%
Waters Corp
NYSE:WAT
Cash Paid for Dividends
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mettler-Toledo International Inc
NYSE:MTD
Cash Paid for Dividends
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Agilent Technologies Inc
NYSE:A
Cash Paid for Dividends
-$276m
CAGR 3-Years
-5%
CAGR 5-Years
-6%
CAGR 10-Years
-5%

IQVIA Holdings Inc
Glance View

Economic Moat
None
Market Cap
32.5B USD
Industry
Life Sciences Tools & Services

In the world of healthcare, IQVIA Holdings Inc. emerges as a formidable player, seamlessly blending data analytics with the imperative of human well-being. Born from the merger of IMS Health and Quintiles in 2016, IQVIA stands at the intersection of technology and life sciences, leveraging vast amounts of health-related data to facilitate more informed decisions in drug development and patient care. The company's vast repository consists of a complex tapestry of dynamic insights from around the globe, which it transforms using sophisticated analytical tools. This technical prowess enables IQVIA to offer solutions that span clinical trials, health information services, and advanced analytics, creating substantial value for pharmaceutical and life sciences companies. At the heart of IQVIA’s revenue model lies its ability to provide strategic services that reduce the time and cost associated with the development of new pharmaceuticals. By offering an integrated suite of services from the initial phases of drug research to post-market monitoring, IQVIA assists its clients in navigating regulatory landscapes and commercializing their products effectively. Its expansive technological infrastructure does not just aid in drug development but also enhances patient engagement, creating digital pathways for more personalized healthcare solutions. Thus, IQVIA earns its keep by not only selling information but also by offering transformative insights that sharpen the competitive edge for its clients in the ever-evolving healthcare sector.

IQV Intrinsic Value
275.79 USD
Undervaluation 33%
Intrinsic Value
Price

See Also

Back to Top